- ISIN
- US9290331084
- CUSIP
- 929033108
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 5, 2021
Highlights
- Market Cap
- $638.72M
- Enterprise Value
- $472.09M
- EPS (TTM)
- -$53.66
- Gross Profit (TTM)
- -$23.00K
- EBITDA (TTM)
- -$1.13B
- Year Range
- $6.50 - $65.80
- Target Price
- $38.50
- ROA (TTM)
- -174.26%
- ROE (TTM)
- 587.06%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
VOR Performance Chart
Vor Biopharma Inc. (VOR) is up 13.5% since the beginning of the year. At $15 per share, VOR is trading 77.4% below its 52-week high of $66. Investors who bought $1,000 worth of VOR shares 5 years ago would now be looking at an investment worth $37.
Loading charts...
Returns By Period
Vor Biopharma Inc. (VOR) has returned 13.53% so far this year and 156.03% over the past 12 months.
Vor Biopharma Inc.
- 1D
- -0.60%
- 1M
- 3.63%
- YTD
- 13.53%
- 6M
- 9.76%
- 1Y
- 156.03%
- 3Y*
- -44.36%
- 5Y*
- -48.26%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
VOR Monthly Returns History
Based on dividend-adjusted daily data since Feb 5, 2021, VOR's average daily return is -0.03%, while the average monthly return is +5.29%. At this rate, an investment would double in approximately 1.1 years.
Historically, 40% of months were positive and 60% were negative. The best month was Jun 2025 with a return of +710.4%, while the worst month was May 2025 at -70.6%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, VOR closed higher 43% of trading days. The best single day was Jun 25, 2025 with a return of +74.3%, while the worst single day was May 8, 2025 at -70.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.61% | 18.77% | 15.54% | -19.67% | 4.47% | -0.80% | 13.53% | ||||||
| 2025 | 27.93% | -23.94% | -33.56% | -5.35% | -70.56% | 710.41% | 27.78% | -4.83% | 23.65% | -50.51% | -65.45% | 57.02% | -41.08% |
| 2024 | 2.22% | 0.00% | 3.04% | -27.43% | -21.51% | -25.93% | -7.12% | -5.88% | -19.93% | 19.97% | -0.93% | 33.41% | -50.67% |
| 2023 | -20.75% | 5.88% | -3.58% | -17.29% | 5.62% | -34.26% | -2.27% | -17.22% | -15.20% | -13.68% | 1.09% | 21.62% | -66.17% |
| 2022 | -29.00% | 9.45% | -33.11% | -5.13% | -26.53% | 18.05% | -7.24% | 11.28% | -22.42% | 20.85% | -4.37% | 44.57% | -42.77% |
| 2021 | 7.00% | -4.14% | -34.62% | -25.12% | -11.61% | -32.87% | 17.33% | 6.74% | 0.32% | -26.64% | 0.69% | -72.35% |
Benchmark Metrics
Vor Biopharma Inc. has an annualized alpha of -21.33%, beta of 1.25, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since February 05, 2021.
- This stock participated in 45.91% of S&P 500 Index downside but only -114.73% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -21.33%
- Beta
- 1.25
- R²
- 0.03
- Upside Capture
- -114.73%
- Downside Capture
- 45.91%
Return for Risk
Risk / Return Rank
VOR ranks 76 for risk / return — better than 76% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Vor Biopharma Inc. (VOR) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VOR | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.85 | ||
| Sortino ratioReturn per unit of downside risk | +0.26 | ||
| Omega ratioGain probability vs. loss probability | 1.33 | 1.32 | +0.01 |
| Calmar ratioReturn relative to maximum drawdown | 1.80 | 2.46 | -0.65 |
| Martin ratioReturn relative to average drawdown | 2.54 | 10.92 | -8.38 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Vor Biopharma Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Vor Biopharma Inc. was 99.72%, occurring on May 9, 2025. The portfolio has not yet recovered.
The current Vor Biopharma Inc. drawdown is 98.63%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -99.72%May 2025 | 4y 2mo | — | 5y 3moFeb 2021 - now |
2021 correction2021 | -16.81%Feb 2021 | 6d | 1d | 7dFeb 2021 - Feb 2021 |
2021 correction2021 | -10.76%Feb 2021 | 0s | 3d | 3dFeb 2021 - Feb 2021 |
2021 pullback2021 | -1.99%Feb 2021 | 0s | 1d | 1dFeb 2021 - Feb 2021 |
Drawdown Indicators
| VOR | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.72% | -56.78% | -42.94% |
Max Drawdown (1Y)Largest decline over 1 year | -87.15% | -9.10% | -78.05% |
Max Drawdown (3Y)Largest decline over 3 years | -96.49% | -18.90% | -77.59% |
Max Drawdown (5Y)Largest decline over 5 years | -99.29% | -25.43% | -73.86% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -98.63% | -3.21% | -95.42% |
Average DrawdownAverage peak-to-trough decline | -88.73% | -10.71% | -78.02% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 61.73% | 2.04% | +59.69% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Vor Biopharma Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Vor Biopharma Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with VOR
Add Vor Biopharma Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with VOR